https://orcid.org/0000-0002-3525-564X
References
- 2023 GINA Report, Global Strategy for Asthma Management and Prevention (GINA 2023). Available at https://ginasthma.org/gina-reports/.
- Ausín P, Navarrete-Rouco ME. Multiple targets, multiple pathways, multiple strategies in the treatment of asthma. Arch Bronconeumol. 2023;59(12):795–796. doi:10.1016/j.arbres.2023.07.032.
- Brusselle GG, Koppelman GH. Biologic therapies for severe asthma. N Engl J Med. 2022;386(2):157–171. doi:10.1056/NEJMra2032506.
- Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, Brightling CE, Griffiths JM, Hellqvist Å, Bowen K, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800–1809. doi:10.1056/NEJMoa2034975.
- Corren J, Menzies-Gow A, Chupp G, Israel E, Korn S, Cook B, Ambrose CS, Hellqvist Å, Roseti SL, Molfino NA, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the pathway and navigator clinical trials. Am J Respir Crit Care Med. 2023;208(1):13–24. doi:10.1164/rccm.202210-2005OC.
- Wechsler ME, Menzies-Gow A, Brightling CE, Kuna P, Korn S, Welte T, Griffiths JM, Sałapa K, Hellqvist Å, Almqvist G, et al. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomized, placebo-controlled, phase 3 study. Lancet Respir Med. 2022;10(7):650–660. doi:10.1016/S2213-2600(21)00537-3.
- Pérez de Llano L, Dávila I, Martínez-Moragón E, Domínguez-Ortega J, Almonacid C, Colás C, García-Rivero JL, Carmona L, García de Yébenes MJ, Cosío BG, et al. Development of a tool to measure the clinical response to biologic therapy in uncontrolled severe asthma: the FEV1, exacerbations, oral corticosteroids, symptoms score. J Allergy Clin Immunol Pract. 2021;9(7):2725–2731. doi:10.1016/j.jaip.2021.01.033.
- Khaleva E, Rattu A, Brightling C, Bush A, Bourdin A, Bossios A, Chung KF, Chaudhuri R, Coleman C, Djukanovic R, et al. Definitions of non-response and response to biological therapy for severe asthma: a systematic review. ERJ Open Res. 2023;9(3):00444–2022. doi:10.1183/23120541.00444-2022.
- van Bragt JJMH, Adcock IM, Bel EHD, Braunstahl G-J, Ten Brinke A, Busby J, Canonica GW, Cao H, Chung KF, Csoma Z, et al. Characteristics and treatment regimens across ERS SHARP severe asthma registries. Eur Respir J. 2020;55(1):1901163. doi:10.1183/13993003.01163-2019.
- Miralles-López JC, Antolín-Amérigo D, García-Moguel I, Domínguez-Ortega J, Delgado-Romero J, Quirce S. Positioning of tezepelumab in severe asthma. J Investig Allergol Clin Immunol. 2024;34(1):1–11. doi:10.18176/jiaci.0949.
- Valverde-Monge M, Sánchez-Carrasco P, Betancor D, Barroso B, Rodrigo-Muñoz JM, Mahillo-Fernández I, Arismendi E, Bobolea I, Cárdaba B, Cruz MJ, et al. Comparison of long-term response and remission to omalizumab and anti-IL-5/IL-5R using different criteria in a real-life cohort of severe asthma patients. Arch Bronconeumol. 2024;60(1):23–32. doi:10.1016/j.arbres.2023.11.011.
- Agache I, Akdis CA, Akdis M, Canonica GW, Casale T, Chivato T, Corren J, Chu DK, Del Giacco S, Eiwegger T, et al. EAACI biologicals guidelines-recommendations for severe asthma. Allergy. 2021;76(1):14–44. doi:10.1111/all.14425.